Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 425809 adjunctive computerized cognitive training in schizophrenia
2018-002740-82Phase 2Unknown
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing BI 425809 + computerized cognitive training with Placebo + computerized cognitive training (2 arms). Primary endpoint: Change from baseline in neurocognitive function. Status: unknown.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2018-002740-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002740-82.